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Abstract
ADAMTS-1, -4, -5 and -9 belong to ‘a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)’
family and more precisely to the proteoglycanases subgroup based on their common ability to degrade chondroitin
sulfate proteoglycans. They have been extensively investigated for their involvement in inflammation-induced
osteoarthritis, and a growing body of evidence indicates that they may be of key importance in the physiological
and pathological central nervous system (CNS). In this review, we discuss the deregulated expression of ADAMTS
proteoglycanases during acute CNS injuries, such as stroke and spinal cord injury. Then, we provide new insights on
ADAMTS proteoglycanases mediating synaptic plasticity, neurorepair, angiogenesis and inflammation mechanisms.
Altogether, this review allows us to propose that ADAMTS proteoglycanases may be original therapeutic targets for
CNS injuries.
Keywords: A disintegrin and metalloproteinase with thrombospondin motifs, Proteoglycanases, Stroke, Spinal cord injury,
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Introduction
The ADAMTS proteases belong to ‘a disintegrin and
metalloproteinase with thrombospondin motifs’ family,
composed of 19 members. They are multi-domain pro-
teins synthesized as pre-pro-enzymes containing from the
N- to the C-terminal end: a peptide signal, a pro-domain,
a zinc binding metalloproteinase domain, a disintegrin-
like domain, a thrombospondin domain, a cysteine-rich
domain, a spacer domain and finally a variable number of
thrombospondin motifs in the C-terminal end [1,2]. Pre-
pro-ADAMTS proteases can be cleaved by furin or furin-
like proteases at the N- and C-terminal positions triggering,
respectively, their activity and their future location within
the extracellular matrix (ECM) via the removal of the pro-
domain, and their substrate specificity [3-11]. When se-
creted, ADAMTS proteases are capable of binding ECM
components via their thrombospondin motifs [3], which
can be then cleaved by the metalloproteinase domain.
ADAMTS proteases are classified in three subfamilies
based on their preference to cleave specific ECM macro-
molecules as follows [12-14]: proteoglycans (ADAMTS-1,
-4, -5, -8, -9, -15 and -20), pro-collagens (ADAMTS-2, -3
and -14) or the von Willebrand factor (ADAMTS-13).
This review will focus on the ADAMTS proteoglycanases
present in the central nervous system (CNS), with special
emphasis on ADAMTS-1, -4, -5 and -9, which are key en-
zymes in the degradation of the aggregating chondroitin
sulfate proteoglycans (CSPGs) [14].
CSPGs are a family of ECM macromolecules charac-
terized by a core protein and a variable number of gly-
cosaminoglycan chains. The major CSPGs found in the
CNS are lecticans (for example, aggrecan, brevican, neu-
rocan and versican), phosphocan and type 2 neurogly-
can. They are concentrated into perineuronal nets
(PNNs) that enwrap a subset of neurons and control the
path finding and guidance of axons during CNS develop-
ment. After CNS injury, CSPGs are rapidly upregulated
within the glial scar and exert both beneficial and dele-
terious effects. For instance, their contribution to the es-
tablishment of a dense glial scar initially constitutes a
protective barrier to limit the propagation of damage,
but also represents a harmful barrier to subsequent neu-
rorepair and neuroplasticity [15].
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While ADAMTS proteoglycanases have been exten-
sively described for their deleterious effect in osteoarth-
ritis, rheumatoid arthritis and vertebral disc degeneration,
it is only recently that their role in the CNS has been
discussed. Therefore, in this review we will provide up-to-
date information about the increasing evidence for the
involvement of ADAMTS proteoglycanases in physio-
logical conditions and CNS pathological disease states
including ischemic stroke and spinal cord injury (SCI).
ADAMTS proteoglycanases in the physiological central
nervous system
ADAMTS proteoglycanases are present in several CNS
structures, including the cortex, the hippocampus, the
striatum and the spinal cord [16-21]. While it is clear that
astrocytes express ADAMTS proteoglycanases in vitro
and in vivo [22-25], their presence in neurons under
physiological conditions is controversial. ADAMTS-4 was
identified in dentate granule neurons and pyramidal cells
by in situ hybridization in rat brains [16]. Similarly, the
expression of ADAMTS-4 was described in cortical neu-
rons in vitro [25], but a more recent investigation failed to
detect ADAMTS-4 in cerebellar granule neurons in vitro
[24]. The presence of ADAMTS-4 has also been reported
in cortical microglia in vitro [24,25] (Table 1).
In the physiological CNS, evidence exists for a role of
ADAMTS proteoglycanases in neural plasticity in vitro
and in vivo. Yuan and collaborators were the first to dis-
cover evidence of the presence of ADAMTS-1, -4 and
ADAMTS-cleaved brevican fragments in the physio-
logical CNS in rats, particularly in plastic regions such
as the hippocampus, suggesting the involvement of the
ADAMTS proteoglycanases in the malleability of PNNs-
containing brevican [16]. Hamel and collaborators (2008)
discovered that a recombinant active ADAMTS-4 pro-
moted neurite growth of cortical neurons in vitro i) by de-
grading CSPGs via its proteolytic activity, and ii) by
activating the MAP/ERK (mitogen activated protein/extra-
cellular signal-regulated kinase) signaling pathway, pre-
sumably due to the activation of tyrosin kinase receptors
by the thrombospondin domain of ADAMTS-4 [26].
However, the concept of CSPGs/ADAMTS proteoglyca-
nases working in concert to regulate plasticity has been
explored only recently in vivo [19]. Interestingly, the ex-
pression of synaptic proteins, such as synaptosomal-
associated protein 25 (SNAP-25), postsynaptic density
protein 95 (PSD-95) and synaptophysin, was decreased in
the developing frontal cortex of ADAMTS-1 deficient fe-
male mice, but not in male mice, suggesting a gender-
specific involvement of ADAMTS-1 in synaptic plasticity.
However, the decline in expression of synaptic proteins
was not accompanied by any modifications of CSPGs
present in PNNs, or by deficits of learning and memory
[19]. Recently, Krstic and collaborators (2012) proposed
ADAMTS-4 and ADAMTS-5 as proteases capable of
cleaving Reelin, an extracellular molecule also involved in
neurodevelopment and in synaptic plasticity induced
learning and memory processes [20]. Interestingly,
ADAMTS-induced cleavage of Reelin is thought to partly
promote its aggregation during aging, and to participate
in the well-known synaptic plasticity defects in elderly
CNS tissues [20].
To summarize, ADAMTS proteoglycanases in the
physiological CNS are synthesized mainly by astrocytes
and expressed in several CNS structures. Interestingly,
increasing evidence suggests that they may play critical
roles in the control of synaptic plasticity during develop-
ment and aging via both proteolytic-dependent and
-independent mechanisms.
ADAMTS proteoglycanases in the pathological central
nervous system
Proteolysis of the ECM can be both beneficial and harm-
ful in several pathological states of the CNS, including
ischemic stroke and SCI [27]. A tight control of the local
environment is crucial to ensure a moderate remodeling
of the ECM in order to promote neuronal plasticity and
survival, or vascular remodeling, after acute CNS injur-
ies. While the expression and associated beneficial or
deleterious effects of matrix metalloproteinases (MMPs)
have been extensively reported in several CNS diseases,
recent publications strongly suggest that the ADAMTS
proteoglycanases may also be important in ECM prote-
olysis in CNS injuries.
ADAMTS proteoglycanases: cytokine- and cell-specific
inducible proteases
Several cytokines, including IL-1β (interleukin-1β), IL-6,
IFN-ɣ (ɣ-interferon), TGF-β (transforming growth factor-
β) and TNF-α (tumor necrosis factor-α), have previously
been described to regulate the expression of ADAMTS
proteoglycanases in non-CNS cell types [28-31]. The
cytokine-rich environment following CNS injuries is there-
fore likely to induce the expression of a complex pattern
of ADAMTS proteoglycanases in a cell- and cytokine-
dependent manner. An increased synthesis of ADAMTS-4,
-5 and -9 by astrocytes was reported after transient middle
cerebral artery occlusion (tMCAO) [32,33]. Similarly, in-
jured neurons were described to synthesize ADAMTS-9
after tMCAO [32], but not after contusion-induced SCI
[34]. Interestingly, ADAMTS-1 was also specifically up-
regulated in cerebral motor neurons after peripheral nerve
injury [35]. Few cytokines have been already proposed to
regulate ADAMTS proteoglycanases expression in the
CNS (Table 1). IL-1α in combination with IL-1 receptor
type 1 promotes ADAMTS-1 transcription in a N1E-115
neuroblast cell line in vitro and in motoneurons after nerve
injury in vivo [35]. ADAMTS-4 mRNA and protein
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expressions were increased by TNF-α in human astrocyte
cultures after 24 hours of treatment, while only upregula-
tion of ADAMTS-1 mRNA or ADAMTS-5 protein levels
were reported. Under similar conditions, IL-1β did not
regulate the transcription of ADAMTS proteoglycanases,
although it seems that there is a trend for an increased
mRNA expression of ADAMTS-4 [23]. Beyond astro-
cytes, microglia and neurons, macrophages that infiltrate
brain or spinal cord after injury may also be an important
source of ADAMTS-1, -4 and -5 [36,37]. Interestingly,
while TNF-α and IFN-ɣ increase the expression of
ADAMTS-4 in macrophages induced by differentiation of
human monocytic cell line THP1 [37], TGF-β negatively
regulates ADAMTS-4 expression through the MAPK and
the Smad-2 and -3 signaling pathways [36]. In similar con-
ditions, it was also described that TGF-β can increase the
synthesis of ADAMTS-4 [38].
Accordingly, modification of ADAMTS proteoglyca-
nases expression has been reported after CNS injuries
including stroke and SCI (Table 2). Yuan and collabora-
tors were first to discover evidence of the increase of
ADAMTS-1, -4 and ADAMTS-cleaved brevican frag-
ments after intraperitoneal injection of kainate-induced
CNS excitoxicity, in the cortex and in the hippocampus,
by pyramidal neurons and dentate granule neurons [16].
After tMCAO, the expression of ADAMTS-1, -4, and -9
Table 1 Cellular expression of ADAMTS proteoglycanases in the physiological and pathological central nervous system
Cell type ADAMTS-1 ADAMTS-4 ADAMTS-5 ADAMTS-9
Astrocytes In vitro: Primary cerebral cultures (mouse) [34] Yes (mRNA) Yes (mRNA) Yes (mRNA) Yes (mRNA)
Primary cortical cultures (rat) [24,25] Yes (mRNA/WB)
Primary cerebral cultures (human) [23]: Yes (mRNA/WB/ICC) Yes (mRNA/WB/ICC) Yes (mRNA/WB/ICC)
- TNF-α treatment ↑ mRNA ↑ mRNA stable mRNA
stable protein ↑ protein stable protein
- IL1-β treatment stable mRNA stable mRNA stable mRNA
In vivo: Brain white matter (human) [22] Yes (IHC) Yes (IHC) Yes (IHC)
Spinal cord white matter (rat) [21] Yes (IHC) Yes (IHC) Yes (IHC)
Injured brain, tMCAO (mouse) [33] Yes (mRNA) Yes (mRNA)
Injured cerebral cortex, tMCAO (rat) [32] Yes (mRNA)
Injured spinal cord, SCI by contusion
(mouse) [34]
Yes (IHC) Yes (IHC) Yes (IHC)
Neurons In vitro: Primary cortical cultures (rat) [25] Yes (WB)
Primary cerebellar granule neurons
cultures (rat) [24]
No (mRNA)
In vivo: Hippocampus, dentate granule neurons
and pyramidal neurons (rat) [16]:
- Physiological conditions No (mRNA) Yes (mRNA)
- Kainate-induced CNS excitoxicity Yes (mRNA) Yes (mRNA)
Injured cerebral cortex, tMCAO (rat) [32] Yes (mRNA)
Injured spinal cord, SCI by contusion
(mouse) [34]
No (IHC)
Microglia In vitro: Primary cerebral/cortical cultures
(rat) [24,25]
Yes (mRNA/WB)
Monocytes / In vitro: THP-1 monocyte cell line (human) [36,37] Yes (mRNA) Yes (mRNA/WB) Yes (mRNA) Yes (mRNA)
Macrophages In vitro: THP-1-derived macrophages
(human) [36,37]:
Yes (mRNA) Yes (mRNA/WB) Yes (mRNA) Yes (mRNA)
- TGF-β treatment [36,38] ↑ mRNA ↑ mRNA/↓ mRNA ↑ mRNA ↑ mRNA
- IFN-ɣ treatment [36,37] ↓ mRNA stable/↑ mRNA stable mRNA ↑ mRNA
- TNF-α treatment [37] ↑ mRNA slight ↑ mRNA
- IL1-β treatment [37] slight ↑ mRNA stable mRNA slight ↑ mRNA
This table depicts the various cell types expressing the major ADAMTS proteoglycanases (ADAMTS-1, -4, -5 and -9) in vitro and/or in vivo under physiological and/
or pathological CNS conditions. It also indicates if ADAMTS proteoglycanases were detected at the mRNA level or at the protein level (WB, ICC, IHC). Numbers
indicate the concerned references. ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; CNS, central nervous system; ICC/IHC, Immunocyto/
histochemistry; IFN-ɣ, ɣ-interferon; IL-1β, interleukin-1β; SCI, spinal cord injury; TGF-β, transforming growth factor-β; tMCAO, transient middle cerebral artery
occlusion; TNF-α, tumor necrosis factor-α; WB, western blot.
Lemarchant et al. Journal of Neuroinflammation 2013, 10:133 Page 3 of 8
http://www.jneuroinflammation.com/content/10/1/133
is upregulated [23,32]. Surprisingly, whereas mRNA
changes were observed in the ipsilateral hemisphere
acutely at 6 and 24 hours after stroke onset, the upregu-
lation of the protein levels of ADAMTS-1 and -4 was
only observed 5 days after injury. Because TNF-α was
shown to promote ADAMTS-1 and -4 mRNA levels as
well as ADAMTS-4 and -5 protein levels in human
astrocyte cultures, it was hypothesized that the increase
of TNF-α expression in the acute phase of stroke may
be responsible for the upregulation of ADAMTS-1 and
-4 by astrocytes [23]. Surprisingly, it is only recently that
the upregulation of ADAMTS-4 and -5 mRNA levels
were detected in astrocytes after tMCAO in mice
24 hours after stroke onset [33]. The expression of
ADAMTS-9 was increased in the acute phase of stroke
within 24 hours post occlusion at both the mRNA and
protein levels, but rather than astrocytes, neurons were
predominantly affected in both contralateral and ipsilateral
hemispheres [32]. Similarly, upregulation of ADAMTS-1,
-5 and -9 mRNA levels were reported in the acute phase
of contusion-induced SCI in mice, whereas no changes to
ADAMTS-4 expression were observed [34]. Tauchi and
colleagues (2012) detected a slight increase of ADAMTS-
4 protein levels associated with a significant increase in
ADAMTS-4 enzymatic activity in spinal cord lysates
from the lesion site one week after contusion-induced
SCI in rats [24]. Demircan and colleagues (2013) also de-
scribed the astrocytes as being a main source of
ADAMTS-1, -5 and -9 in the spinal cord after SCI.
However, they did not observe the presence of ADAMTS-
9 in neurons after SCI [34].
To summarize, CNS injuries including ischemic stroke
or SCI lead to the upregulation of different combinations
of ADAMTS proteoglycanases, respectively ADAMTS-1,
-4, -9 and ADAMTS-1, -5, -9 (Table 2). A cytokine regu-
lation and/or cell-specific expression of ADAMTS pro-
teoglycanases expression strongly suggest that each of
them may be associated to a specific local turnover of
CSPGs, assuming that they have non-redundant and co-
operative functions in the CNS. Several clues indicate
that ADAMTS proteoglycanases may have both benefi-
cial and deleterious effects after CNS injuries as de-
scribed hereafter and summarized in Figure 1.
ADAMTS proteoglycanases: inflammatory and
anti-angiogenic proteases in the central nervous system?
ADAMTS proteoglycanases and macrophage infiltration
A growing body of evidence suggests that ADAMTS
proteoglycanases may be involved in the neuroinflamma-
tory response after CNS injury by promoting the infiltra-
tion of macrophages into the CNS:
1. ADAMTS-4 is increased during the differentiation of
human monocytes into macrophages in vitro [37] and
is required for macrophages invasion in vitro [38].
2. Versican is the primary CSPG present in the
vasculature and is a potent substrate for ADAMTS
proteoglycanases [39], which begs the question of
Table 2 Deregulated expression of ADAMTS proteoglycanases after central nervous system injuries
STROKE SCI
tMCAO model Contusion model
Early stagea Late stageb Early stagec Late staged
ADAMTS-1
mRNA level ↑ (rat) [23] stable (rat) [23] ↑ (mouse) [34]
Protein level stable (rat) [23] ↑ (rat) [23]
ADAMTS-4
mRNA level ↑ (rat/mouse) [23,33] stable (rat) [23] stable (mouse) [34]
Protein level stable (rat) [23] ↑ (rat) [23] slight ↑ (rat) [24]
Activity ↑ (rat) [24]
ADAMTS-5
mRNA level ↑ (mouse) [33] slight ↑ (rat) [23] ↑ (mouse) [34]
Protein level
ADAMTS-9
mRNA level ↑ (rat) [32] ↑ (mouse) [34]
Protein level ↑ (rat) [32] not detected (rat) [32]
This table depicts the expression and/or activity of the major ADAMTS proteoglycanases (ADAMTS-1, -4, -5 and -9) in the time course of CNS injuries, including
ischemic stroke (tMCAO model) and spinal cord injury (contusion model). a6 to 24 h, b5 to 7d after stroke onset; c3 to 24 h, d7d after SCI onset. Numbers indicate
the concerned references. ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; CNS, central nervous system; SCI, spinal cord injury; tMCAO,
transient middle cerebral artery occlusion.
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whether upregulation of the ADAMTS
proteoglycanases at the neurovascular unit may
participate in the leakage of the blood brain/spinal
cord barrier after ischemic stroke or SCI. It would
be consistent with local degradation of versican by
ADAMTS proteoglycanases synthesized by
endothelial cells [40-42] and/or monocytes/
macrophages [36].
Altogether, it can be hypothesized that ADAMTS pro-
teoglycanases, particularly ADAMTS-4, may be a key
player of the macrophage infiltration into the CNS after
injury either directly or indirectly by promoting the leak-
age of the blood brain/spinal cord barrier.
ADAMTS proteoglycanases and angiogenesis
The involvement of ADAMTS proteases has been largely
investigated in angiogenesis mechanisms occurring in
cancer, yet similar mechanisms may also occur in the
CNS. Both proteinase-dependent and independent anti-
angiogenic functions for most of the ADAMTS proteases,
including proteoglycanases, have been described [42-45].
For instance, it has been proposed that ADAMTS proteo-
glycanases can negatively regulate angiogenesis via the
sequestration of the most potent pro-angiogenic factor,
VEGF (vascular endothelial growth factor) or via the
release of anti-angiogenic fragments derived from throm-
bospondin type 1 and 2 motifs. Besides its pro-angiogenic
effect, VEGF has also been shown to promote vascular
permeability, neuroinflammation, neuritic growth and
neuroprotection particularly after ischemic stroke or SCI
[46]. Therefore, it is possible to hypothesize that the
sequestration of VEGF by endogenous ADAMTS pro-
teoglycanases may have both protective and harm-
ful effects in the CNS. To conclude, the effect of
ADAMTS proteoglycanases in angiogenesis processes
after acute CNS injuries remains largely unknown and
deserves further investigation.
ADAMTS proteoglycanases and neurorepair
Neurorepair including neuroregeneration and remyelina-
tion is compromised in the chronic phase of stroke or
SCI partly because of an overexpression of CSPGs
[47,48]. In parallel with the upregulation of CSPGs
within the glial scar, ischemic stroke is also associated
with degradation of PNNs containing CSPGs at the le-
sion site, but also in the peri-ischemic area and the
contralateral hemisphere after permanent MCAO. Al-
though the degradation of the PNNs occurred predom-
inantly in the lesion core and was associated with the
invasion of monocytes/macrophages, the transient re-
duction of neurons containing PNNs in the peri-
ischemic area or the contralateral hemisphere is more
likely associated with an attempt at neurorepair [49]. It
is tempting to hypothesize that after CNS injuries, the
loss of PNNs may be caused by increased local secretion
Figure 1 Roles of ADAMTS proteoglycanases in the physiological and pathological central nervous system. Schematic representation of
described (filled lines)/hypothetical (dotted lines) roles of ADAMTS proteoglycanases in the physiological (green) and pathological (red) CNS, with
corresponding major references listed below. This schema also illustrates that ADAMTS proteoglycanases can achieve several functions in the
physiological and pathological CNS via the cleavage of their substrates, so far CSPGs or Reelin, but also independently of their proteolytic activity.
ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; CNS, central nervous system; CSPGs, chondroitin sulfate proteoglycans.
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of neuronal ADAMTS proteoglycanases (as described
for ADAMTS-1 and ADAMTS-9) triggering adverse
effects: neuroinflammation in the lesion core and an at-
tempt at neuroplasticity in surrounding tissues. How-
ever, these attempts at axonal regeneration/collateral
sprouting are too transient and/or unsuccessful to effi-
ciently penetrate the repellant CSPGs-rich glial scar and
to improve long term functional recovery.
The inhibition of CSPGs can be relieved by the bacter-
ial enzyme chondroitinase ABC which removes the
chondroitin sulfate chains from the core proteins, thus
promoting axonal regeneration/collateral sprouting of a
wide variety of neuron tracts and functional recovery
after stroke or SCI [49-57]. However, the core proteins re-
main intact and can still inhibit neuroregeneration/remye-
lination. ADAMTS proteoglycanases are physiological
enzymes capable of achieving the complete degradation of
CSPGs [1,2]. Surprisingly, evidence that ADAMTS pro-
teoglycanases may improve neurite growth and axonal
regeneration/collateral sprouting has recently emerged:
1. Hamel and collaborators (2008) reported that a
recombinant active ADAMTS-4 can promote neurite
growth of cortical neurons in vitro dependently or
independently of its proteolytic activity as described
above [26].
2. Cua and collaborators (2013) reported that
ADAMTS-4 was more efficient at degrading CSPGs
and inducing subsequent neurite growth in vitro
than chondroitinase ABC or MMPs [58].
3. The treatment of mice submitted to contusion-
induced SCI with recombinant ADAMTS-4
improves axonal regeneration/collateral sprouting of
serotoninergic fibers and subsequent functional
recovery via the degradation of neurocan [24].
In addition to the inhibition of axonal regeneration/
collateral sprouting in CNS injuries, CSPGs are also
strongly upregulated within the white matter where they
contribute to the inhibition of remyelination of injured
axons. Interestingly, chondroitinase ABC can prevent
CSPGs-inhibition of remyelination in vitro and in vivo after
contusion-induced SCI in rats and in a lysolecithin-
induced demyelination model in mice [47,48,59]. Moreover,
olfactory ensheathing cell-based therapies promote remye-
lination after acute injuries [60] and these cells were re-
cently reported to express ADAMTS-4 [61,62]. This raises
the question of whether ADAMTS-4 or any ADAMTS
proteoglycanases could improve remyelination of injured
axons more efficiently than chondroitinase ABC does.
To conclude, the overexpression of ADAMTS proteo-
glycanases induced by acute CNS injuries such as stroke
or SCI seems harmful in the acute phase through enhan-
cing neuroinflammation, and beneficial (or at least safe)
in later phases to initiate neurorepair (Figure 1). A com-
bination approach may represent an attractive thera-
peutic opportunity: first, the administration of an
inhibitor of ADAMTS proteoglycanases activity, such as
TIMP-3 (tissue inhibitor of metalloproteinases-3) [63],
or an inhibitor of their synthesis, such as the anti-
inflammatory compound WIN-34B [29], in the acute
phase of CNS injuries to overcome ADAMTS-induced
macrophage infiltration; then, the administration of ac-
tive ADAMTS proteoglycanases in the chronic phase of
CNS injuries to enhance neuroregeneration/neuroplasti-
city/remyelination, by using already commercially avail-
able recombinant proteins, or by using lentiviral gene
therapy approach in cell transplantation-based therapies.
However, the administration of any therapeutic molecule
to treat CNS disorders is challenging; in addition to find-
ing the most appropriate timing, their passage across the
blood brain/spinal cord barrier can also be problematic
[64]. However, nasal delivery of therapeutic molecules to
the brain allows them to bypass the barrier and repre-
sents a safe and convenient system for pre-clinical and
clinical studies [65].
Conclusions
Exciting evidence for the involvement of ADAMTS pro-
teoglycanases in the CNS in mechanisms governing syn-
aptic plasticity during development and aging has been
proposed quite recently and has emphasized the
proteolytic-dependent and -independent actions of these
ADAMTS proteoglycanases. However, more research is
required to determine whether ADAMTS proteoglyca-
nases have redundant spatiotemporal expressions and
functions in the physiological and also pathological
CNS. After CNS injuries such as stroke and SCI, it
seems obvious that ADAMTS proteoglycanases may be
detrimental in the acute phase of injury while they may
have a beneficial role later on as summarized in Figure 1.
Even though their roles in angiogenesis and macrophage
infiltration within the injured CNS have not been ad-
dressed yet, the early inhibition of ADAMTS proteogly-
canases synthesis/activity after brain or spinal cord
injuries may represent a rational therapeutic approach to
limit the invasion of macrophages and/or to promote
angiogenesis. This review clearly supports the postulate
that the ADAMTS proteoglycanases, in particular
ADAMTS-4, should be considered as key proteases to
promote neurorepair after CNS injuries.
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